PL2887923T3 - Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu - Google Patents

Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu

Info

Publication number
PL2887923T3
PL2887923T3 PL13831463.8T PL13831463T PL2887923T3 PL 2887923 T3 PL2887923 T3 PL 2887923T3 PL 13831463 T PL13831463 T PL 13831463T PL 2887923 T3 PL2887923 T3 PL 2887923T3
Authority
PL
Poland
Prior art keywords
polyoxyl
treatment
fatty acid
ophthalmic formulation
ocular conditions
Prior art date
Application number
PL13831463.8T
Other languages
English (en)
Inventor
Ashim K. Mitra
Sidney L. WEISS
Eugene J. Mcnally
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50148510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2887923(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Publication of PL2887923T3 publication Critical patent/PL2887923T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13831463.8T 2012-08-24 2013-08-23 Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu PL2887923T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261693189P 2012-08-24 2012-08-24
PCT/US2013/056513 WO2014032026A1 (en) 2012-08-24 2013-08-23 Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions

Publications (1)

Publication Number Publication Date
PL2887923T3 true PL2887923T3 (pl) 2023-08-14

Family

ID=50148510

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13831463.8T PL2887923T3 (pl) 2012-08-24 2013-08-23 Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu

Country Status (16)

Country Link
US (5) US8980839B2 (pl)
EP (2) EP2887923B1 (pl)
AU (1) AU2013305539B2 (pl)
CA (2) CA3050298A1 (pl)
DK (1) DK2887923T3 (pl)
ES (1) ES2948387T3 (pl)
FI (1) FI2887923T3 (pl)
HK (1) HK1211867A1 (pl)
HR (1) HRP20230559T1 (pl)
HU (1) HUE062145T2 (pl)
LT (1) LT2887923T (pl)
MX (1) MX361858B (pl)
PL (1) PL2887923T3 (pl)
PT (1) PT2887923T (pl)
SI (1) SI2887923T1 (pl)
WO (1) WO2014032026A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
WO2015179527A1 (en) * 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
US20180133217A1 (en) * 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
WO2017083410A1 (en) * 2015-11-12 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
NZ785158A (en) * 2016-02-29 2025-03-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
WO2017190114A1 (en) 2016-04-29 2017-11-02 i-novion, Inc. Liquid pentablock co-polymer formulations for sustained delivery of therapeutics
PT3548091T (pt) * 2016-11-29 2022-01-21 Oculis SA Preparação de complexos sólidos de ciclodextrina para administração oftálmica de ingrediente farmacêutico ativo
CN107334734B (zh) * 2017-07-10 2020-03-17 浙江大学 一种西罗莫司或其衍生物的眼用制剂
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
WO2021001366A1 (en) 2019-07-01 2021-01-07 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
CA3148362C (en) * 2019-08-18 2024-02-13 Bo Liang In-situ gel forming ophthalmic formulations containing difluprednate
JP2023504205A (ja) * 2019-12-09 2023-02-01 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 角膜病変の治療のための生体分子
US11918275B2 (en) 2021-04-30 2024-03-05 Cilag Gmbh International Electrosurgical adaptation techniques of energy modality for combination electrosurgical instruments based on shorting or tissue impedance irregularity
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
JP2024521968A (ja) 2021-06-14 2024-06-04 サン ファーマシューティカル インダストリーズ リミテッド 白内障手術を受ける患者において使用するための、シクロスポリン製剤
US20240342086A1 (en) * 2021-08-20 2024-10-17 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2406A (en) * 1841-12-30 Construction of railroad-scbapers fob cleaning te-ie tracks from sl
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) * 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US6816968B1 (en) * 1998-07-10 2004-11-09 Silverbrook Research Pty Ltd Consumable authentication protocol and system
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
EP1435910B9 (en) 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
AU2002365167A1 (en) 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US6949664B2 (en) 2002-04-01 2005-09-27 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
US20040213782A1 (en) 2003-02-03 2004-10-28 Pharmacia Corporation Compositions of an aquaporin modulating agent and an aqueous humor modulating agent for the treatment of elevated intraocular pressure
JP2004238346A (ja) * 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
EP1755537A4 (en) 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
US20060020563A1 (en) * 2004-07-26 2006-01-26 Coleman Christopher R Supervised neural network for encoding continuous curves
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
CA2588166A1 (en) 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2006132342A1 (ja) 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
CN102772358A (zh) 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
EP1983977A4 (en) 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
FR2904568B1 (fr) * 2006-08-03 2008-09-05 Dynastar Skis Sa Procede de fabrication d'une planche de glisse
EP2120920A4 (en) 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) * 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US20090048929A1 (en) * 2007-08-15 2009-02-19 Paul Im Authenticated travel record
JP5327809B2 (ja) 2007-08-29 2013-10-30 わかもと製薬株式会社 ラタノプロスト含有水性医薬組成物
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
JP5668476B2 (ja) * 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
BRPI0912302A2 (pt) * 2008-05-28 2015-10-20 Alcon Res Ltd emulsões autopreservados
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
CA2763819A1 (en) * 2009-06-02 2010-12-09 Nian WU Pure peg-lipid conjugates
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
CA2773597A1 (en) * 2009-09-17 2011-03-24 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
BR112012028437A2 (pt) 2010-05-07 2016-07-19 Sun Pharma Advanced Res Co Ltd solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
BR112014028069A2 (pt) 2012-05-11 2017-08-08 Cipla Ltd composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
WO2015179527A1 (en) 2014-05-23 2015-11-26 Ocular Technologies Sarl Topical formulations and uses thereof
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
WO2017083410A1 (en) 2015-11-12 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
NZ785158A (en) 2016-02-29 2025-03-28 Sun Pharmaceutical Ind Ltd Topical cyclosporine-containing formulations and uses thereof
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
FI2887923T3 (fi) 2023-06-30
AU2013305539A1 (en) 2015-03-12
HUE062145T2 (hu) 2023-10-28
US20150165048A1 (en) 2015-06-18
US20160256520A1 (en) 2016-09-08
US20160256521A1 (en) 2016-09-08
HRP20230559T1 (hr) 2023-09-15
PT2887923T (pt) 2023-06-28
WO2014032026A1 (en) 2014-02-27
DK2887923T3 (da) 2023-07-03
US9937225B2 (en) 2018-04-10
US20150148299A1 (en) 2015-05-28
US8980839B2 (en) 2015-03-17
EP2887923B1 (en) 2023-04-05
HK1211867A1 (en) 2016-06-03
LT2887923T (lt) 2023-07-10
MX361858B (es) 2018-12-18
MX2015002239A (es) 2016-01-08
ES2948387T3 (es) 2023-09-11
EP2887923A1 (en) 2015-07-01
US10441630B2 (en) 2019-10-15
EP4218729A1 (en) 2023-08-02
CA2914472A1 (en) 2014-02-27
CA2914472C (en) 2019-09-03
SI2887923T1 (sl) 2023-09-29
CA3050298A1 (en) 2014-02-27
EP2887923A4 (en) 2016-03-30
AU2013305539B2 (en) 2018-08-02
US20140057854A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
SI2887923T1 (sl) Oftalmična formulacija polioksilnega lipida ali polioksilne maščobne kisline in zdravljenje očesnih stanj
IL260585B (en) Compositions and methods for treating retinal diseases
IL238432B (en) Methods and devices for the treatment of eye diseases in humans
BR112012032948A2 (pt) dispositivos injectores e método de suprimento de solução oftálmica à córnea do olho
ZA201402615B (en) Prevention and treatment of ocular conditions
ZA201408592B (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
IL249821A0 (en) Omega-3 fatty acid ester compositions
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
IL230957A0 (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
PL2827713T3 (pl) Wodne koncentraty środka chwastobójczego zawierające estry alkilowe kwasu tłuszczowego, amidy kwasu tłuszczowego lub triglicerydowe estry kwasu tłuszczowego, oraz sposoby zastosowania
IL257403A (en) A stable emulsion to prevent irritation to the skin and skin of those who use it
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
IL235762A0 (en) Stable emulsion to prevent skin irritation and items that use it
PL3556346T3 (pl) Estry do leczenia stanów zapalnych oczu
PL2814463T3 (pl) Okulistyczne kompozycje farmaceutyczne i sposoby ich wytwarzania i stosowania
IL231374A (en) Use of epa and dha to treat eye disease
IL235874A0 (en) Treatment of ocular inflammatory diseases by laquinimod
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
ZA201408993B (en) Pharmaceutical formulation for bedwetting and method of use thereof
EP3013425A4 (en) Treatment and diagnosis of ocular disease
EP2734188A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EYE SURFACE ALLERGIES
IL239078A0 (en) Protein for use in the treatment of eye diseases
IL239512B (en) Analogues and derivatives of alkyl fatty acids, pharmaceutical formulations containing them and their uses
GB201223337D0 (en) Treatment of non eye infections and non refractive disorders
IL231052A0 (en) (Bacterio) chlorophyll photosensitizers for the treatment of eye diseases and disorders